Biogen's second-quarter results show that sales of Alzheimer's disease therapy Leqembi are continuing to ramp up, driven by a new formulation that avoids the need for infusion clinic visits.

UK-based startup Oyster Therapeutics has raised $60 million in first-round financing that will be used to advance its tau ...

Hims & Hers is also offering compounded formulations of other unapproved peptides, including sermorelin, which some people ...

The FDA has ordered all GLP-1 receptor agonist manufacturers to add a warning to the label of their products for a rare eye ...

The takeover deal – worth up to $1.15 billion including $550 million in upfront cash – will upgrade the Dutch biotech's ...

Asundexian has been approved by the FDA under the Sunharbo brand name for use in combination with antiplatelet therapy to ...